| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $1,323,482 | 3 | 100 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | 0 | $0 | 2 | $140,306 | $-140,306 |
| Wright Richard M. | Former Officer | 0 | $0 | 1 | $1.18M | $-1.18M |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Over the last 12 months, insiders at Celldex Therapeutics, Inc. have bought $0 and sold $1.32M worth of Celldex Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Celldex Therapeutics, Inc. have bought $164,165 and sold $5.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,500 shares for transaction amount of $308,430 was made by Marucci Anthony S (PRESIDENT & CEO) on 2024‑11‑11.
| 2025-12-04 | Sale | Jimenez Freddy A. | SVP & GENERAL COUNSEL | 4,166 0.0062% | $29.09 | $121,210 | -12.15% | |
| 2025-11-13 | Sale | Wright Richard M. | Former Officer | 49,298 0.0751% | $24.00 | $1.18M | +9.63% | |
| 2025-08-13 | Sale | Jimenez Freddy A. | SVP & GENERAL COUNSEL | 771 0.0012% | $24.77 | $19,096 | +2.78% | |
| 2024-11-11 | Marucci Anthony S | PRESIDENT & CEO | 11,500 0.0178% | $26.82 | $308,430 | -13.49% | ||
| 2024-06-14 | Sale | Martin Samuel Bates | SVP AND CFO | 17,172 0.0259% | $35.42 | $608,315 | -25.61% | |
| 2024-06-14 | Sale | Crowley Elizabeth | SR. VP & CPDO | 30,000 0.0446% | $34.87 | $1.05M | -25.61% | |
| 2024-06-07 | Sale | Crowley Elizabeth | SR. VP & CPDO | 15,000 0.0226% | $35.06 | $525,873 | -25.71% | |
| 2024-06-07 | Sale | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 45,000 0.0682% | $35.26 | $1.59M | -25.71% | |
| 2024-06-03 | Sale | Jimenez Freddy A. | SVP & GENERAL COUNSEL | 8,006 0.0122% | $33.60 | $269,002 | -21.50% | |
| 2024-06-03 | Sale | Wright Richard M. | SR. VP & CCO | 46,844 0.0716% | $33.72 | $1.58M | -21.50% | |
| 2024-06-03 | Sale | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 58,369 0.089% | $33.65 | $1.96M | -21.50% | |
| 2024-05-30 | Sale | Martin Samuel Bates | SVP AND CFO | 35,000 0.0538% | $34.05 | $1.19M | -21.48% | |
| 2024-05-30 | Sale | Crowley Elizabeth | SR. VP & CPDO | 38,597 0.0586% | $33.64 | $1.3M | -21.48% | |
| 2024-05-30 | Sale | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 38,719 0.0595% | $34.07 | $1.32M | -21.48% | |
| 2024-05-30 | Sale | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 20,853 0.0317% | $33.73 | $703,334 | -21.48% | |
| 2022-12-07 | Sale | KELER TIBOR | EXECUTIVE VP & CSO | 16,860 0.0356% | $36.93 | $622,611 | -7.66% | |
| 2022-08-17 | Sale | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 19,000 0.0411% | $37.30 | $708,715 | -4.79% | |
| 2022-08-17 | Sale | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 1,355 0.0029% | $36.38 | $49,289 | -4.79% | |
| 2022-08-15 | Sale | Marucci Anthony S | PRESIDENT & CEO | 120,000 0.2564% | $37.66 | $4.52M | -6.57% | |
| 2022-08-15 | Sale | Wright Richard M. | SR. VP & CCO | 15,328 0.0328% | $37.71 | $578,048 | -6.57% |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | 30796 0.0463% | $706,460.24 | 1 | 3 | <0.0001% |
| Wright Richard M. | Former Officer | 20833 0.0314% | $477,909.02 | 0 | 4 | |
| MEDAREX INC | 10 percent owner | 2960848 4.4558% | $67.92M | 0 | 2 | |
| RYAN UNA S | President & CEO | 898713 1.3525% | $20.62M | 2 | 0 | |
| SEARS PETER A | director | 72739 0.1095% | $1.67M | 1 | 0 | |
| ELLBERGER LARRY | director | 53500 0.0805% | $1.23M | 5 | 1 | +3.43% |
| Marucci Anthony S | PRESIDENT & CEO | 40284 0.0606% | $924,114.96 | 6 | 1 | +107.81% |
| PAREKH RAJESH R | director | 40000 0.0602% | $917,600.00 | 1 | 3 | <0.0001% |
| WARD J BARRIE | director | 35774 0.0538% | $820,655.56 | 0 | 1 | |
| CATLIN AVERY W | Sr. VP & CFO | 35109 0.0528% | $805,400.46 | 5 | 3 | +20.69% |
| Martin Samuel Bates | SVP AND CFO | 28125 0.0423% | $645,187.50 | 1 | 6 | +500.67% |
| PENNER HARRY JR | director | 13416 0.0202% | $307,763.04 | 1 | 1 | +13.16% |
| LIPTON KAREN SHOOS | director | 13333 0.0201% | $305,859.02 | 1 | 1 | +3.2% |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 13383 0.0201% | $307,006.02 | 1 | 4 | +500.67% |
| MARINO JAMES J | director | 12704 0.0191% | $291,429.76 | 2 | 0 | +231.19% |
| Crowley Elizabeth | SR. VP & CPDO | 9074 0.0137% | $208,157.56 | 0 | 5 | |
| KELER TIBOR | EXECUTIVE VP & CSO | 7357 0.0111% | $168,769.58 | 5 | 1 | +101.05% |
| KYLE FREDERICK W | director | 7000 0.0105% | $160,580.00 | 0 | 2 | |
| SCHALLER CHARLES R | director | 5000 0.0075% | $114,700.00 | 4 | 0 | +1.11% |
| SHANNON TIMOTHY M | director | 3200 0.0048% | $73,408.00 | 1 | 0 | +11.03% |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 2115 0.0032% | $48,518.10 | 1 | 3 | +105.94% |
| Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 1860 0.0028% | $42,668.40 | 1 | 4 | +275.1% |
| Davis Thomas Andrew | Sr. VP & CMO | 1489 0.0022% | $34,157.66 | 1 | 0 | +3.2% |
$8,217,280 | 112 | 46.33% | $1.41B | |
$831,902,292 | 108 | 9.34% | $1.7B | |
$607,159,124 | 92 | 3.55% | $1.57B | |
$21,345,882 | 83 | 94.45% | $1.46B | |
$100,473,344 | 83 | 9.53% | $1.47B | |
$54,590,806 | 65 | 21.84% | $1.52B | |
$1,103,317,478 | 60 | 36.54% | $1.64B | |
$530,111,731 | 35 | 8.69% | $1.53B | |
Celldex Therapeutics, Inc. (CLDX) | $1,603,489 | 30 | 98.90% | $1.52B |
$82,281,805 | 29 | -1.52% | $1.73B | |
$135,656,796 | 20 | 30.66% | $1.49B | |
$154,554,190 | 14 | 29.60% | $1.63B | |
$2,788,839 | 12 | 6.73% | $1.5B | |
$18,336,420 | 12 | 24.03% | $1.41B | |
$2,859,892 | 10 | 29.21% | $1.77B | |
$93,268,646 | 8 | -37.22% | $1.55B | |
$46,235,722 | 6 | -31.77% | $1.42B | |
$3,200,000 | 5 | -11.36% | $1.59B | |
$103,599,972 | 2 | -36.81% | $1.39B |
| Increased Positions | 86 | +39.63% | 6M | +7.81% |
| Decreased Positions | 87 | -40.09% | 8M | -11.1% |
| New Positions | 28 | New | 1M | New |
| Sold Out Positions | 27 | Sold Out | 1M | Sold Out |
| Total Postitions | 216 | -0.46% | 71M | -3.28% |
| Kynam Capital Management, Lp | $164,781.00 | 9.24% | 6.1M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $156,658.00 | 8.79% | 5.8M | +567,677 | +10.85% | 2025-09-30 |
| Blackrock, Inc. | $148,717.00 | 8.34% | 5.51M | -44,028 | -0.79% | 2025-09-30 |
| Fmr Llc | $134,026.00 | 7.52% | 4.96M | -477,030 | -8.77% | 2025-09-30 |
| Vanguard Group Inc | $106,813.00 | 5.99% | 3.95M | -2,532 | -0.06% | 2025-09-30 |
| Point72 Asset Management, L.P. | $105,175.00 | 5.9% | 3.89M | +1M | +38.98% | 2025-09-30 |
| Bellevue Group Ag | $96,093.00 | 5.39% | 3.56M | +250,100 | +7.56% | 2025-09-30 |
| Commodore Capital Lp | $81,795.00 | 4.59% | 3.03M | -421,665 | -12.22% | 2025-09-30 |
| State Street Corp | $76,766.00 | 4.31% | 2.84M | +436,639 | +18.15% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $64,352.00 | 3.61% | 2.38M | -1M | -37.59% | 2025-09-30 |